Amplia Therapeutics Limited
ASX: ATX.AX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Christopher J. Burns
- Employees
- 1
- Headquarters
- Melbourne, Australia
- IPO year
- 2014
- Market cap
- A$66.7M
- Website
- https://www.ampliatx.com
Loading ATX…
Loading profile data…Frequently asked questions about ATX
What does Amplia Therapeutics Limited (ATX.AX) do?
Amplia Therapeutics Limited, a pharmaceutical company, focuses on development of focal adhesion kinase (FAK) inhibitors for oncology and chronic fibrosis in Australia. The company's product pipeline includes AMP945, an inhibitor of FAK, for pancreatic cancer and idiopathic pulmonary fibrosis, as well as other cancers and fibrotic diseases indica...
Where does ATX.AX trade?
Amplia Therapeutics Limited (ATX.AX) trades on the Australian Securities Exchange.
What sector is ATX.AX in?
Amplia Therapeutics Limited (ATX.AX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Amplia Therapeutics Limited?
Christopher J. Burns is the chief executive officer of Amplia Therapeutics Limited (ATX.AX).
Where is Amplia Therapeutics Limited headquartered?
Amplia Therapeutics Limited is headquartered in Australia.
Does ATX.AX pay a dividend?
Amplia Therapeutics Limited (ATX.AX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ATX.AX go public?
Amplia Therapeutics Limited (ATX.AX) completed its initial public offering in 2014.